West Pharmaceutical Services (WST)
(Delayed Data from NYSE)
$308.15 USD
-3.05 (-0.98%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $308.05 -0.10 (-0.03%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth C Momentum D VGM
Income Statements
Fiscal Year end for West Pharmaceutical Services, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2,950 | 2,887 | 2,832 | 2,147 | 1,840 |
Cost Of Goods | 1,821 | 1,751 | 1,656 | 1,379 | 1,234 |
Gross Profit | 1,129 | 1,136 | 1,176 | 768 | 606 |
Selling & Adminstrative & Depr. & Amort Expenses | 453 | 402 | 424 | 361 | 309 |
Income After Depreciation & Amortization | 676 | 734 | 752 | 407 | 297 |
Non-Operating Income | 31 | -46 | 5 | 3 | 4 |
Interest Expense | 9 | 8 | 8 | 8 | 9 |
Pretax Income | 698 | 680 | 749 | 401 | 292 |
Income Taxes | 122 | 115 | 107 | 73 | 59 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 18 | 21 | 20 | 17 | 9 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 593 | 586 | 662 | 346 | 242 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 593 | 586 | 662 | 346 | 242 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 813 | 855 | 875 | 516 | 400 |
Depreciation & Amortization (Cash Flow) | 137 | 121 | 122 | 109 | 103 |
Income After Depreciation & Amortization | 676 | 734 | 752 | 407 | 297 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 75.30 | 75.80 | 76.30 | 75.80 | 75.40 |
Diluted EPS Before Non-Recurring Items | 8.08 | 8.58 | 8.58 | 4.76 | 3.24 |
Diluted Net EPS (GAAP) | 7.88 | 7.73 | 8.67 | 4.57 | 3.21 |
Fiscal Year end for West Pharmaceutical Services, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 702.10 | 695.40 | 732.00 | 747.40 | 753.80 |
Cost Of Goods | 472.10 | 465.20 | 453.80 | 459.10 | 462.40 |
Gross Profit | 230.00 | 230.20 | 278.20 | 288.30 | 291.40 |
SG&A, R&D, and Dept/Amort Expenses | 103.80 | 107.40 | 117.30 | 111.00 | 108.90 |
Income After SG&A, R&D, and Dept/Amort Expenses | 126.20 | 122.80 | 160.90 | 177.30 | 182.50 |
Non-Operating Income | 4.00 | 6.20 | 8.50 | 12.60 | 5.10 |
Interest Expense | 1.50 | 1.60 | 1.20 | 2.90 | 2.70 |
Pretax Income | 128.70 | 127.40 | 168.20 | 187.00 | 184.90 |
Income Taxes | 21.90 | 16.40 | 34.50 | 29.40 | 34.80 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 4.50 | 4.30 | 3.30 | 3.70 | 5.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 111.30 | 115.30 | 137.00 | 161.30 | 155.10 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 111.30 | 115.30 | 137.00 | 161.30 | 155.10 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 73.70 | 74.30 | 75.00 | 75.30 | 75.40 |
Diluted EPS Before Non-Recurring Items | 1.52 | 1.56 | 1.83 | 2.16 | 2.11 |
Diluted Net EPS (GAAP) | 1.51 | 1.55 | 1.83 | 2.14 | 2.06 |